Market Closed -
Nasdaq
04:30:01 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
3.546
USD
|
+9.44%
|
|
+7.45%
|
-50.47%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
297.7
|
365.6
|
111.8
|
24.35
|
95.38
|
46.06
|
-
|
-
|
Enterprise Value (EV)
1 |
243.5
|
299.3
|
111.8
|
24.35
|
95.38
|
46.06
|
46.06
|
46.06
|
P/E ratio
|
-6.44
x
|
-6.7
x
|
-2.96
x
|
-0.59
x
|
-3.54
x
|
-1.39
x
|
-1.66
x
|
-2.03
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
72.1
x
|
24.1
x
|
3.71
x
|
0.56
x
|
2.82
x
|
2.33
x
|
0.99
x
|
0.65
x
|
EV / Revenue
|
72.1
x
|
24.1
x
|
3.71
x
|
0.56
x
|
2.82
x
|
2.33
x
|
0.99
x
|
0.65
x
|
EV / EBITDA
|
-9,234,771
x
|
-11,520,029
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-3,125,101
x
|
-912,171
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
9,635
|
12,394
|
13,980
|
13,606
|
13,322
|
12,989
|
-
|
-
|
Reference price
2 |
30.90
|
29.50
|
8.000
|
1.790
|
7.160
|
3.546
|
3.546
|
3.546
|
Announcement Date
|
3/16/20
|
3/30/21
|
3/28/22
|
4/26/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.131
|
15.14
|
30.17
|
43.11
|
33.88
|
19.8
|
46.48
|
70.35
|
EBITDA
|
-32.24
|
-31.74
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-39.99
|
-33.7
|
-41.84
|
-34.03
|
-25.08
|
-35.72
|
-33.28
|
-28.4
|
Operating Margin
|
-968.07%
|
-222.56%
|
-138.68%
|
-78.95%
|
-74.03%
|
-180.45%
|
-71.59%
|
-40.36%
|
Earnings before Tax (EBT)
1 |
-45.36
|
-47.51
|
-35.84
|
-37.43
|
-26.29
|
-35.8
|
-33.28
|
-28.4
|
Net income
1 |
-46.03
|
-48.29
|
-36.65
|
-41.01
|
-26.96
|
-35.8
|
-33.28
|
-28.4
|
Net margin
|
-1,114.31%
|
-318.92%
|
-121.5%
|
-95.14%
|
-79.58%
|
-180.83%
|
-71.59%
|
-40.36%
|
EPS
2 |
-4.800
|
-4.400
|
-2.700
|
-3.010
|
-2.020
|
-2.560
|
-2.130
|
-1.750
|
Free Cash Flow
|
-
|
-
|
-35.79
|
-26.7
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-118.63%
|
-61.94%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/30/21
|
3/28/22
|
4/26/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
8.112
|
9.158
|
9.062
|
8.573
|
10.21
|
15.26
|
8.347
|
9.82
|
8.838
|
6.874
|
3.409
|
4.431
|
4.56
|
7.394
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-6.892
|
-11.44
|
-7.29
|
-7.746
|
-6.354
|
-12.64
|
-
|
-9.345
|
-5.095
|
-3.427
|
-
|
-8.676
|
-8.826
|
-8.763
|
-
|
Operating Margin
|
-84.96%
|
-124.86%
|
-80.45%
|
-90.35%
|
-62.21%
|
-82.85%
|
-
|
-95.16%
|
-57.65%
|
-49.85%
|
-
|
-195.8%
|
-193.55%
|
-118.52%
|
-
|
Earnings before Tax (EBT)
|
-10.02
|
-4.789
|
-8.4
|
-7.493
|
-5.023
|
-16.52
|
-
|
-10.06
|
-4.451
|
-5.972
|
-
|
-8.676
|
-8.826
|
-8.763
|
-
|
Net income
|
-10.22
|
-5.601
|
-8.596
|
-7.68
|
-5.201
|
-19.54
|
-
|
-10.24
|
-4.635
|
-6.077
|
-
|
-8.676
|
-8.826
|
-8.763
|
-
|
Net margin
|
-126.04%
|
-61.16%
|
-94.86%
|
-89.58%
|
-50.93%
|
-128.04%
|
-
|
-104.27%
|
-52.44%
|
-88.41%
|
-
|
-195.8%
|
-193.55%
|
-118.52%
|
-
|
EPS
2 |
-0.7000
|
-0.4000
|
-0.6000
|
-0.5600
|
-0.3800
|
-1.440
|
-0.4500
|
-0.7700
|
-0.3500
|
-0.4600
|
-0.7100
|
-0.6300
|
-0.6200
|
-0.6000
|
-0.6100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/28/22
|
5/12/22
|
8/12/22
|
11/14/22
|
4/26/23
|
5/17/23
|
8/11/23
|
11/14/23
|
3/28/24
|
5/14/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
54.2
|
66.4
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-35.8
|
-26.7
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.43
|
1.5
|
8.95
|
5.61
|
-
|
-
|
-
|
-
|
Capex / Sales
|
10.34%
|
9.9%
|
29.65%
|
13.02%
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/30/21
|
3/28/22
|
4/26/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
3.546
USD Average target price
6
USD Spread / Average Target +69.20% Consensus |
1st Jan change
|
Capi.
|
---|
| -50.47% | 46.06M | | +38.51% | 727B | | +33.05% | 599B | | -6.23% | 354B | | +18.78% | 328B | | +1.35% | 277B | | +16.00% | 243B | | +8.09% | 205B | | -5.77% | 203B | | +6.19% | 164B |
Other Pharmaceuticals
|